EICHOR
● Active Not Recruiting
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
Condition: Metastatic Castrate-sensitive Prostate Cancer · Sponsor: Janssen Research & Development, LLC
About this study
The purpose of the study is to determine if the intermittent use of androgen-deprivation therapy (ADT) in participants with metastatic castrate-sensitive prostate cancer (mCSPC) who reached a prostate-specific antigen (PSA) level \< 0.2 nanograms/millilitres (ng/mL) after 6 months of treatment with apalutamide and ADT combination therapy provides non-inferior radiographic progression-free survival (rPFS) and a reduced burden of hot flashes measured as 18-month percent change in severity adjusted hot flash score.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (93)
| Urology Centers Of Alabama | Homewood, Alabama, United States | — |
| Del Sol Research Management, LLC | Tucson, Arizona, United States | — |
| Arizona Urology Specialists | Tucson, Arizona, United States | — |
| Arkansas Urology | Little Rock, Arkansas, United States | — |
| Urology Associates of Central California | Fresno, California, United States | — |
| VA Medical Center | San Francisco, California, United States | — |
| Sansum Clinic Pharm | Santa Barbara, California, United States | — |
| Colorado Clinical Research | Lakewood, Colorado, United States | — |
| Advanced Urology Institute | Daytona Beach, Florida, United States | — |
| Associated Urological Specialists LLC | Chicago Ridge, Illinois, United States | — |
| Advanced Urology Associates | Joliet, Illinois, United States | — |
| Urology of Indiana | Greenwood, Indiana, United States | — |
+ 81 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05884398